AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27216112
Drug: Digital Cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Cognitive Behavioural Therapy (dCBT) delivered via web and/or mobile channels
Trial: 27216112
Drug: Digital Cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Cognitive Behavioural Therapy (dCBT)
Trial: 25244260
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (antiretroviral therapy and counseling only)
Trial: 23013802
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg intravenously every 6 hours for 7 days) and Clonidine (0.1 mg per tube every 12 hours for 7 days)
Trial: 20006165
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 10 mg
Trial: 18835099
Drug: Acidic phosphate
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acidic phosphate buffer (pH 5.2) at 40 ml/h
Trial: 18835099
Drug: Acidic phosphate
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acidic phosphate buffer (pH 5.2) at 20 ml/h
Trial: 18835099
Drug: Normal phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal phosphate buffer (pH 7.3) at 40 ml/h
Trial: 18835099
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline at 40 ml/h
Trial: 16438016
Drug: Cisatracurium Bolus
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium Bolus (0.15 mg/kg) - Group A
Trial: 16438016
Drug: Cisatracurium Infusion
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium Infusion (0.18 mg/kg/h) - Group B
Trial: 12885803
Drug: Rhenium-188 hydroxyethylidenediphosphonate
RxNorm normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - two injections (group B)
Trial: 12885803
Drug: Rhenium-188 hydroxyethylidenediphosphonate
RxNorm normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - single injection (group A)
Trial: 10475142
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of distigmine (14C-distigmine-bromide)
Trial: 10475142
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 14C-distigmine-bromide
Trial: 1912107
Drug: Biperiden 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 8 mg
Trial: 29465346
Drug: Tocilizumab 4
RxNorm normalized name: tocilizumab 400 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 4 mg/kg with methotrexate
Trial: 29465346
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg with methotrexate
Trial: 19800061
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (0.25 mg/d on days 1, 2, and 3 of the menstrual cycle)
Trial: 19800061
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GnRH antagonist supplementation)
Trial: 18341675
Drug: Phosphodiesterase 4
RxNorm normalized name: Phosphodiesterase 4 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase 4 inhibitors
Trial: 16841667
Drug: Gegen Qinlian
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gegen Qinlian Decoction (GQD) combined with insulin treatment
Trial: 16841667
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (insulin treatment alone)
Trial: 9121664
Drug: 14G intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14G intravenous catheter
Trial: 9121664
Drug: 16G intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16G intravenous catheter
Trial: 7688829
Drug: Flutamide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (375 mg p.o. daily)
Trial: 7688829
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) (100 mg p.o. daily)
Trial: 2953226
Drug: Intracoronary nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicardipine (0.2 mg)
Trial: 30463608
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual care with financial incentives (up to $550) for participating in the New York Smoker's Quitline, using nicotine replacement therapy, and achieving biochemically confirmed smoking cessation at 2 months and 6 months.
Trial: 26306520
Drug: Pegfilgrastim administration
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administration 24 hours after chemotherapy (cohort A)
Trial: 26306520
Drug: Pegfilgrastim administration
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administration 72 hours after chemotherapy (cohort B)
Trial: 26306520
Drug: Pegfilgrastim administration
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administration 96 hours after chemotherapy (cohort C)
Trial: 24865694
Drug: Low-dose CTPA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CTPA (80 kVp, 75 ml CM)
Trial: 24865694
Drug: Normal-dose CTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose CTPA (100 kVp, 100 ml CM)
Trial: 2039963
Drug: Telebrix 38
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telebrix 38 (2% solution in water)
Trial: 2039963
Drug: Gastrografin (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (2% solution in water)
Trial: 7215768
Drug: Intravenous sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sulprostone
Trial: 7215768
Drug: Extraamniotic injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraamniotic injections
Trial: 7215768
Drug: Extra-amniotic injections
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic injections following intramuscular injection for priming
Trial: 7215768
Drug: Priming administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming administration
Trial: 28939746
Drug: Radotinib 300
RxNorm normalized name: Radotinib
DrugBank: Radotinib (DB12323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radotinib 300 mg
Trial: 28939746
Drug: Radotinib 400
RxNorm normalized name: Radotinib
DrugBank: Radotinib (DB12323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radotinib 400 mg
Trial: 31592954
Drug: Basic LV
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic LV services (LV devices dispensed without therapy)
Trial: 28329346
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) 8 mg/kg
Trial: 28329346
Drug: Ivermectin (IVM)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin (IVM) 200 µg/kg
Trial: 26083950
Drug: DC-TC (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-TC (in patients with no evidence of disease at treatment start)
Trial: 26083950
Drug: TC (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (in patients with no evidence of disease at treatment start)
Trial: 17623225
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (15 ml/day, 8.1 g ALA)
Trial: 17623225
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (15 ml/day, 11.2 g LA)
Trial: 15708217
Drug: Concurrent verbal
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent verbal interference task during encoding
Trial: 15708217
Drug: Concurrent visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent visual interference task during encoding
Trial: 10546421
Drug: Ammonium lactate
RxNorm normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ammonium lactate 12% lotion
Trial: 10546421
Drug: Liposome-based moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome-based moisturizing lotion
Trial: 7051452
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg chloroquine base per kg body-weight (single dose)
Trial: 7051452
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg chloroquine base per kg body-weight (given over three days)
Trial: 25378059
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of subcutaneous immunotherapy (IT3)
Trial: 25378059
Drug: 5 years
RxNorm normalized name: Dymadon 5 Years Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 years of subcutaneous immunotherapy (IT5)
Trial: 24988825
Drug: Gabapentin (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (started at 300 mg daily, increased to a maximum of 1800 mg)
Trial: 24988825
Drug: Naproxen (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (started at 250 mg daily, increased to a maximum of 1500 mg)
Trial: 19487623
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/5 mL) for 12 weeks, mean maximum dosage 16.5 mg/d (maximum 20 mg/d)
Trial: 19487623
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/5 mL) for 12 weeks
Trial: 19558735
Drug: Optimal PEEP
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal PEEP plus sigh breaths (twice the baseline tidal volume, plateau pressure < 40 cm H(2)O) every 25 breaths
Trial: 14714839
Drug: Implant-supported overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported overdentures
Trial: 8186061
Drug: Litoxetine 10
RxNorm normalized name: Litoxetine
DrugBank: Litoxetine (DB15038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litoxetine 10 mg
Trial: 8186061
Drug: Litoxetine 25
RxNorm normalized name: Litoxetine
DrugBank: Litoxetine (DB15038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litoxetine 25 mg
Trial: 31219734
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statin, dual antiplatelet therapy, and beta-blockers prescribed to 79.6% of patients upon discharge.
Trial: 31219734
Drug: Renin-angiotensin-aldosterone system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin-aldosterone system inhibitor prescribed to 67.3% of patients with LVEF ≤40%.
Trial: 31219734
Drug: Beta-blocker prescribed
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker prescribed to 91.8% of patients with LVEF ≤40%.
Trial: 31219734
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with statins in patients with prior history of CAD.
Trial: 31219734
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with antiplatelets in patients with prior history of CAD.
Trial: 31219734
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with beta-blockers in patients with prior history of CAD.
Trial: 31219734
Drug: Optimal LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal LDL-C of <70 mg/dl at admission in CAD patients.
Trial: 26920640
Drug: Humalog® KwikPen™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humalog® KwikPen™ 200 units/mL (IL 200 pen)
Trial: 26920640
Drug: Humalog KwikPen
RxNorm normalized name: HumaLOG KwikPen
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humalog KwikPen 100 units/mL (IL 100 pen)
Trial: 22705939
Drug: Mindful Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Movement Program (MMP) - 12 weekly sessions
Trial: 15988706
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg daily for 12 weeks
Trial: 12699298
Drug: Calcium enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium enhancement of estrogen's effects, with a recommended intake of 30 to 40 mmol Ca/d and sufficient vitamin D (approximately 25 microg vitamin D/d) to maintain serum 25(OH)D levels above 80 nmol/L.
Trial: 12699298
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation in the presence of bone active agents.
Trial: 12699298
Drug: Newer anabolic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer anabolic agents requiring higher levels of calcium repletion.
Trial: 10480774
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A)
Trial: 10480774
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P)
Trial: 10480774
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P)
Trial: 7815337
Drug: Cocaine HCl
RxNorm normalized name: cocaine HCl
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine HCl (80 mg/70 kg p.o.)
Trial: 7815337
Drug: Cocaine (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20, 40, 80 and 120 mg/70 kg, oral and intranasal)
Trial: 7815337
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 and 0.50 mg/70 kg p.o.)
Trial: 7815337
Drug: Cocaine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (oral and intranasal)
Trial: 7815337
Drug: Cocaine (training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (training dose)
Trial: 6980657
Drug: midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.3 mg kg‐1
Trial: 6980657
Drug: thiopentone 3
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thiopentone 3 mg kg‐1
Trial: 31869428
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg s.c. for 3 days
Trial: 31869428
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg p.o. for 3 days
Trial: 31869428
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg for 10 days
Trial: 26869679
Drug: Midodrine (MH)
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine (MH) 10 mg
Trial: 26869679
Drug: L-NAME 1
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME 1 mg/kg
Trial: 30003563
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous hydrocortisone infusion (CSHI)
Trial: 24517155
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone (OHC)
Trial: 22356132
Drug: linagliptin +
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin + high-dose metformin
Trial: 22356132
Drug: linagliptin +
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin + low-dose metformin
Trial: 22356132
Drug: high-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose metformin
Trial: 22356132
Drug: low-dose metformin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose metformin
Trial: 22356132
Drug: open-label linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: open-label linagliptin + high-dose metformin
Trial: 22356132
Drug: linagliptin +
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin + metformin
Trial: 19910547
Drug: Clinical physical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical physical therapy (PT)
Trial: 17559146
Drug: IROX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IROX (oxaliplatin 85 mg/m² and irinotecan 200 mg/m² every 3 weeks)
Trial: 11740322
Drug: Clarithromycin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (7.5 mg/kg/dose twice a day for 7 days)
Trial: 11740322
Drug: Erythromycin (13.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (13.3 mg/kg/dose three times a day for 14 days)
Trial: 7995001
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole
Trial: 2646839
Drug: lotrolan (0.27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lotrolan (0.27 osmol/kg, 280 mg J/ml)
Trial: 2646839
Drug: lopromide (0.77
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopromide (0.77 osmol/kg, 370 mg J/ml)
Trial: 2646839
Drug: Amidotrizoate (2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amidotrizoate (2.1 osmol/kg, 370 mg J/ml)
Trial: 28662049
Drug: SD+AMX+MET (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD+AMX+MET (both 500mg x 3 times daily TID) for 3 days (group B)
Trial: 28662049
Drug: SD+AMX+MET (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD+AMX+MET (both 500mg x 3 times daily TID) for 7 days (group C)
Trial: 26199386
Drug: Cilengitide 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2,000 mg administered intravenously twice weekly (arm A)
Trial: 26199386
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (arm B)
Trial: 23922748
Drug: Partially hydrogenated
RxNorm normalized name: SOY OIL,PARTIALLY HYDROGENATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrogenated soybean oil providing 15.7 g/day of TFA (trans18:1)
Trial: 17429507
Drug: Homeopathic preparations
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic preparations and practice
Trial: 8857120
Drug: Intratracheal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratracheal administration of preservative-free fentanyl
Trial: 8857120
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of preservative-free fentanyl
Trial: 1542851
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) radiotherapy: five times 2 Gy daily fractions to a total dose of 10 Gy
Trial: 1542851
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) radiotherapy: ten times 2 Gy (8 patients) or five times 3.5 Gy (20 patients)
Trial: 24819685
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment outcome
Trial: 1542851
Drug: Treatment failures
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failures related to Brooker score
Trial: 27522159
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral immunotherapy (E-OIT) at goal maintenance doses of 300 mg/d
Trial: 27522159
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral immunotherapy (E-OIT) at goal maintenance doses of 3000 mg/d